Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.85 EUR | -1.93% | +1.59% | +72.07% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.07% | 1.77B | |
+18.02% | 125B | |
+14.08% | 108B | |
-7.13% | 23.64B | |
+2.74% | 22.39B | |
-11.88% | 17.78B | |
-41.74% | 16.43B | |
-13.87% | 16.34B | |
+1.06% | 13.56B | |
+25.48% | 11.59B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating